MPM Oncology Impact Management »

Miragen Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Miragen Therapeutics (VRDN) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Miragen Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Miragen Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Miragen Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $13M 650k 19.56
2024-03-31 $11M 614k 17.51
2023-09-30 $3.9M 255k 15.34
2023-06-30 $6.1M 255k 23.79

More positions owned by MPM Oncology Impact Management

DBV Technologies S A Sponsored Ads (DBVT)
Cullinan Therapeutics Common (CGEM)
Aktis Oncology Common
Liquidia Corporation Common (LQDA)
Alumis Common (ALMS)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Corcept Therapeutics Common (CORT)
Trevi Therapeutics Common (TRVI)
Dianthus Therapeutics Common (DNTH)
Xenon Pharmaceuticals Common (XENE)
MoonLake Immunotherapeutics Class A Ord (MLTX)
Travere Therapeutics Common (TVTX)
Evommune Common (EVMN)

View all positions for MPM Oncology Impact Management

Top funds holding Miragen Therapeutics

FMR
BlackRock
Vanguard Group
Bellevue Group
Vanguard Capital Management
Fairmount Funds Management
VR Adviser
State Street Corporation
Paradigm Biocapital Advisors
Citadel Advisors
Kynam Capital Management
Geode Capital Management
Balyasny Asset Management
Novo A/S
Baker Bros. Advisors

View all funds holding Miragen Therapeutics